Table 1.
Demographical data as well as treatment related data of 212 long-term treated CD-patients in whom results of antibody testing were available.
| n = | Age (years) | Sex (f/m) | Weight (kg) | Onset of CD (years) | Duration of therapy (years) | TSUI-score | PSSTE subj.-score (VAS: 0–100) | CDQ24 total score | Dosis (uDU) 1:4:10 Bot:Dys:Neuro | |
|---|---|---|---|---|---|---|---|---|---|---|
| Group I ELISA-negative |
173 | MV: 59.8 SD: 12.0 |
102/71 | MV: 75.5 SD: 18.3 |
MV: 42.8 SD: 11.2 |
MV: 11.2 SD: 5.5 |
MV: 4.8 SD: 3.2 |
MV: 46.3 SD: 27.3 |
MV: 21.78 SD: 16.99 |
MV: 761 SD: 177 |
| Group II ELISA-positive |
39 | MV: 64.6 SD: 9.7 |
26/13 | MV: 74.4 SD: 15.4 |
MV: 44.1 SD: 10.8 |
MV: 13.5 SD: 4.2 |
MV: 6.1 SD: 3.7 |
MV: 48.3 SD: 29.8 |
MV: 22.49 SD: 18.70 |
MV: 850 SD: 164 |
| Entire cohort |
212 | MV: 61.0 SD: 11.8 |
128/84 | MV: 75.2 SD: 17.9 |
MV: 43.1 SD: 11.1 |
MV: 11.7 SD: 5.3 |
MV: 4.9 SD: 3.3 |
MV: 46.6 SD: 27.9 |
MV: 21.91 SD: 17.27 |
MV: 764 SD: 170 |
| Significance (I against II) |
0.018 | 0.114 n.s. |
0.76 n.s. |
0.532 n.s. |
0.022 | 0.015 | 0.696 n.s. |
0.534 n.s. |
0.001 |
Group I (ELISA-negative patients), Group II (ELISA-positive patients) and all patients (entire cohort). For subgroup definition see methods.
CD, cervical dystonia; ELISA, enzyme-linked immunosorbent assay; MV, mean value; PSSTE, severity of CD and associated treatment effect as scored by patients; SD, standard deviation.